BHA and BHT in Cosmetics: The 1986 Cancer Classification, and Why the EU Just Set New Limits Anyway

Georden Jones, Founder, The Peer Review · Last updated: August 29, 2026

---

The Short Answer

Butylated hydroxyanisole and butylated hydroxytoluene, BHA and BHT, are synthetic antioxidant preservatives used to stop cosmetic oils and food fats from turning rancid. Both carry a cancer warning that traces back to a specific 1986 finding: BHA caused forestomach tumors in rats and hamsters fed high dietary doses, which led the International Agency for Research on Cancer to classify it Group 2B, possibly carcinogenic to humans, and California to add it to its Proposition 65 warning list [1][3]. What most warning labels and ingredient-avoidance lists leave out is that IARC itself convened a scientific workshop in 2003 and concluded the mechanism behind those forestomach tumors does not apply to humans, since the forestomach is a rodent-specific digestive organ humans do not have, yet the agency has never formally revised BHA’s original classification [1][2]. This is not a settled case of an old warning being quietly ignored. European regulators took the human-relevance question seriously enough to reassess it directly: in April 2026, the EU’s Scientific Committee on Consumer Safety issued a final opinion concluding BHA is safe in leave-on and rinse-off cosmetic products at concentrations up to 0.07%, explicitly dismissing the rodent forestomach mechanism as not applicable to people while still setting a real, enforceable numeric limit rather than declaring the ingredient unrestricted [4]. BHT, a related but chemically distinct antioxidant, carries a different concern profile entirely, centered on suspected endocrine-disrupting activity rather than the forestomach cancer question, and the EU caps it at 0.8% in most leave-on and rinse-off products, dropping to just 0.1% in toothpaste and 0.001% in mouthwash [5].

Evidence Rating: Mixed Signals. BHA’s original Group 2B classification, based on rodent forestomach tumors, is General Consensus as a documented finding, but the human relevance of that specific mechanism has been reassessed and dismissed by both IARC’s own 2003 workshop and the EU’s 2026 safety opinion, even though the formal IARC classification itself was never revised [1][2][4]. BHT’s endocrine-disruption concern is Not Enough to Say, an active area of regulatory scrutiny that prompted an EU safety review rather than a confirmed, established human health hazard [5][6]. Both ingredients remain permitted for cosmetic use in Canada, the US, and the EU as of 2026, but only the EU has set specific, science-reviewed numeric concentration limits for each one individually.

---

Table of Contents

• Identify: Two Related Ingredients With Two Different Concerns
• Where It Hides
• How It Affects You and Enters the Body
• Investigate: The 1986 Classification vs. the 2026 Reassessment
• What Canada Regulates, and What It Does Not
• What Canada, the US, and the EU Require
• Inform: What This Means for You
• Improve: How to Reduce Risk Without Overreacting
• What This Does Not Mean
• FAQ
• The Bottom Line
• References

---

Identify: Two Related Ingredients With Two Different Concerns

BHA and BHT are both synthetic phenolic antioxidants, chemically related but distinct compounds that manufacturers add in small amounts to prevent oils, fats, and fragrance compounds from oxidizing and turning rancid over a product’s shelf life [1][5]. They show up in both food and cosmetics for the same underlying reason: without an antioxidant, unsaturated fats and oils degrade, developing off odors and potentially forming their own breakdown byproducts, so the antioxidant is doing a genuine, functional preservation job rather than serving a purely cosmetic purpose [5].

The two ingredients carry different specific concerns, and conflating them obscures more than it clarifies. BHA’s regulatory history centers on a single, well-documented 1986 finding: high dietary doses caused forestomach tumors in rats and hamsters, a rodent-specific digestive structure that does not exist in humans, which is the basis for both its original IARC classification and the reason regulators have since revisited whether that finding says anything meaningful about human risk [1][2]. BHT’s concern profile is different, centered on suspected endocrine-disrupting properties that prompted its inclusion on the EU’s priority list for follow-up safety review, a separate scientific question from BHA’s cancer classification entirely [5][6].

---

Where It Hides

BHA and BHT appear across a wide range of cosmetic, personal care, and food products where oxidation prevention matters [1][5]:

• Lipstick, lip balm, and other oil-based lip products. A high-relevance category given the partial ingestion that comes with any product applied to the lips.
• Moisturizers, creams, and lotions. Used at low concentrations to protect the oil phase of the formula from turning rancid.
• Hair care products and styling products. Particularly formulas containing natural oils or fragrance compounds prone to oxidation.
• Deodorants and antiperspirants. A common antioxidant use case in this product category.
• Some packaged foods, including cereals, snack foods, and preserved meats, where both ingredients are separately approved food additives regulated under a different framework than cosmetics.
• Fragrance formulations broadly, since many fragrance oils are themselves prone to oxidation and benefit from an added antioxidant.

---

How It Affects You and Enters the Body

The exposure pathway differs meaningfully depending on product type, which matters for weighing the two separate concerns behind BHA and BHT [1][5]:

• Skin absorption is the primary route for cosmetic use. BHA and BHT are added at low percentages to leave-on and rinse-off cosmetics, and dermal absorption is the exposure pathway the EU’s 2026 safety opinion specifically evaluated in setting its 0.07% limit for BHA [4].
• Lip products introduce a partial ingestion route, the same consideration that applies to petrolatum and several other Fine Print entries, since anything applied to the lips is partially swallowed during normal use over the course of a day.
• Dietary exposure from approved food uses is a separate, additive pathway. Both BHA and BHT are approved food antioxidants in Canada, the US, and the EU, meaning a person’s total exposure across both cosmetics and food sources is higher than cosmetic use alone would suggest, though each use is separately regulated and assessed [5].
• The original 1986 forestomach finding came from high-dose dietary exposure in rodents, a different route, dose, and species than typical human cosmetic exposure, which is precisely the gap the 2003 IARC workshop and the 2026 EU safety opinion both examined [1][2][4].

---

Investigate: The 1986 Classification vs. the 2026 Reassessment

1. BHA’s original cancer classification (a real finding, with a documented human-relevance gap). IARC classified BHA as Group 2B, possibly carcinogenic to humans, in 1986 based on studies showing it caused benign and malignant forestomach tumors in rats and hamsters given high dietary doses over their lifetimes [1]. This classification directly triggered California’s Proposition 65 listing, which is why BHA-containing products sold in that state often carry a cancer warning label [3]. The critical detail most warning labels omit: the forestomach is an organ specific to rodents used in laboratory studies, and humans do not have an equivalent structure, which is exactly the concern IARC’s own convened scientific workshop examined in 2003, concluding the mechanism behind BHA’s forestomach tumors was not relevant to human cancer risk [1][2]. Despite reaching that conclusion, IARC has never formally revised BHA’s original 1986 classification, leaving the Group 2B label technically in place even after the agency’s own experts questioned its human applicability [2].

2. The 2026 EU reassessment (a fresh, direct look at the same question). Rather than relying on a decades-old classification either way, the EU’s Scientific Committee on Consumer Safety conducted its own dedicated risk assessment of BHA in cosmetics, issuing a preliminary opinion in November 2025 and a final opinion in April 2026 that reached the same conclusion twice: the forestomach tumor mechanism is not relevant to human dermal exposure, and BHA is safe in leave-on and rinse-off cosmetic products at concentrations up to 0.07% [4]. This is a meaningfully different regulatory posture than simply ignoring an old warning. The SCCS did not declare BHA unrestricted. It set a specific, numeric, science-reviewed limit and explicitly excluded oral care products and any use involving inhalation exposure from its safety conclusion, reflecting that the forestomach-irrelevance finding applies specifically to the dermal exposure route it evaluated [4].

3. BHT’s separate endocrine-disruption question (an open scientific review, not a settled hazard). BHT was placed in the EU’s higher-priority group for endocrine disruptor follow-up review based on suspected hormone-related activity, a different concern from BHA’s cancer classification entirely [5][6]. The SCCS’s existing safety opinion on BHT sets concentration limits, up to 0.8% in most leave-on and rinse-off products, dropping sharply to 0.1% in toothpaste and 0.001% in mouthwash, reflecting extra caution around oral mucosal exposure specifically [5]. The endocrine-disruption question itself remains under active regulatory scrutiny rather than resolved in either direction.

---

What Canada Regulates, and What It Does Not

Neither BHA nor BHT appears by name on Health Canada’s Cosmetic Ingredient Hotlist, the country’s list of prohibited and concentration-restricted cosmetic ingredients. Both remain permitted for cosmetic use in Canada under the general cosmetic safety framework, without a Canada-specific numeric concentration limit comparable to the EU’s 0.07% BHA cap or its tiered BHT limits [7]. This means a Canadian-market cosmetic containing BHA or BHT is not required to meet the same specific concentration ceiling the EU’s 2026 safety opinion established, relying instead on the manufacturer’s general obligation to formulate a safe product.

Health Canada has an open, ongoing consultation process for updating the Hotlist, running from November 2025 to February 2026 as of this writing, but the published proposals from that consultation have not specifically named BHA or BHT for new restriction as of this article’s last update [7].

---

What Canada, the US, and the EU Require

Requirement	Canada	United States	European Union
BHA concentration limit in cosmetics	No specific numeric limit; not listed on the Cosmetic Ingredient Hotlist [7]	No specific federal numeric limit	Capped at 0.07% in leave-on and rinse-off dermal products as of the SCCS’s final April 2026 opinion; excludes oral care and inhalation-risk products [4]
BHT concentration limit in cosmetics	No specific numeric limit; not listed on the Cosmetic Ingredient Hotlist [7]	No specific federal numeric limit	Capped at 0.8% in most leave-on/rinse-off products, 0.1% in toothpaste, 0.001% in mouthwash [5]
Cancer warning requirement	None	None federally; California’s Proposition 65 requires a warning label on products sold in that state specifically, based on the original 1986 IARC classification [3]	None beyond the concentration cap itself
Basis for current regulatory approach	General cosmetic safety obligation, no ingredient-specific review published	No dedicated federal safety reassessment identified	Dedicated, ingredient-specific SCCS safety opinions for both BHA and BHT, most recently updated in 2026 for BHA [4][5]

The clearest distinction across the three: the EU is the only jurisdiction that has conducted a dedicated, published, ingredient-specific safety reassessment of BHA addressing the human-relevance question directly, and it did so as recently as April 2026. Canada and the US both permit the ingredient without a comparable numeric limit or a published reassessment of the 1986 finding, leaving California’s decades-old Proposition 65 warning as the only consumer-facing signal in North America tied to the original classification.

---

Inform: What This Means for You

• BHA’s cancer warning traces to a specific, rodent-only mechanism that both IARC’s own 2003 workshop and the EU’s 2026 safety review concluded does not apply to humans, even though the formal 1986 classification was never officially revised [1][2][4].
• The EU did not simply dismiss the old warning. It set a real, enforceable concentration limit, 0.07%, based on a fresh 2026 risk assessment, which is a more rigorous outcome than either ignoring the ingredient or banning it outright [4].
• BHT’s concern is a genuinely different, separate question from BHA’s, centered on suspected endocrine-disrupting activity that remains under active regulatory review rather than confirmed either way [5][6].
• Neither ingredient has a Canada-specific numeric concentration limit, meaning Canadian-market products rely on general safety formulation rather than the same reviewed ceiling EU products must meet [7].
• California’s Proposition 65 warning label for BHA is the only concrete consumer signal in North America, and it reflects the original 1986 classification rather than the more recent human-relevance findings [3].

---

Improve: How to Reduce Risk Without Overreacting

1. Do not treat a BHA cancer warning as equivalent to a confirmed human hazard. The specific mechanism behind the original classification has been reassessed by both IARC’s own workshop and the EU’s 2026 opinion and found not applicable to human exposure [1][2][4].
2. If you want to align with the most rigorously reviewed standard available, look for products formulated to meet the EU’s 0.07% BHA and tiered BHT limits, since these reflect the most recent, dedicated safety assessments of either ingredient [4][5].
3. Pay closer attention to BHT in products used near the mouth, given the EU’s much stricter limits for toothpaste and mouthwash compared to leave-on skin products, reflecting genuine caution around oral mucosal exposure [5].
4. The endocrine-disruption question around BHT is worth monitoring rather than acting on definitively today, since it remains an active area of regulatory review rather than a resolved hazard [5][6].
5. If you are specifically avoiding either ingredient for personal preference reasons, both are easy to identify on an ingredient list by their full names or the initials BHA and BHT.

---

What This Does Not Mean

This is not a case for dismissing BHA’s warning label as meaningless marketing fear, and it is not a case for treating the ingredient as an active carcinogen despite two separate, credentialed scientific reviews concluding the underlying mechanism does not apply to humans. IARC’s original 1986 classification was a real, documented laboratory finding, not a fabricated concern, and the agency’s own 2003 workshop and the EU’s independent 2026 risk assessment both reaching the same human-relevance conclusion is a meaningfully stronger evidence pattern than a single dismissal would be. At the same time, the fact that the formal Group 2B classification has never been officially revised, more than two decades after IARC’s own experts questioned it, is a legitimate reason warning labels like California’s Proposition 65 notice continue to appear on BHA-containing products, and that gap between the technical classification and the current scientific understanding is worth knowing rather than assuming has been quietly resolved. BHT’s situation is different again: its endocrine-disruption question remains genuinely open, not settled in either direction, which is exactly why the EU continues to review it rather than either clearing it entirely or restricting it further.

---

FAQ

---

The Bottom Line

BHA’s cancer warning traces back to a specific 1986 finding, forestomach tumors in rodents fed high dietary doses, and both IARC’s own 2003 workshop and the EU’s dedicated April 2026 safety reassessment concluded that exact mechanism does not apply to human exposure, even though the formal classification was never officially updated [1][2][4]. The EU did not simply drop the concern. It set a real, science-reviewed concentration limit of 0.07% for dermal cosmetic use, the most rigorous, current answer available anywhere on this specific question [4]. BHT carries a separate concern entirely, suspected endocrine-disrupting activity that remains under active regulatory review, with the EU capping it more strictly in oral-contact products like toothpaste and mouthwash [5][6]. Neither Canada nor the US has set a comparable ingredient-specific numeric limit for either compound, leaving California’s decades-old Proposition 65 warning as the only concrete consumer signal in North America, one that reflects the original 1986 finding rather than the more recent, more thorough scientific reassessment.

Stay curious, stay critical.
Georden

---

References

1. IARC. “Butylated Hydroxyanisole (BHA),” Overall Evaluations of Carcinogenicity, Volume 40.
2. “Butylated Hydroxyanisole: Carcinogenic Food Additive to Be Avoided or Harmless Antioxidant Important to Protect Food Supply?” Regulatory Toxicology and Pharmacology, 2021.
3. Center for Science in the Public Interest. “Butylated Hydroxyanisole (BHA).”
4. European Commission, Scientific Committee on Consumer Safety. “Final Opinion: Scientific Advice on Butylated Hydroxyanisole (BHA), SCCS/1682/25,” April 2026.
5. European Commission. “Butylated Hydroxytoluene (BHT),” Public Health.
6. David Suzuki Foundation. “Toxic Ingredient to Avoid: BHA and BHT.”
7. Health Canada. “Cosmetic Ingredient Hotlist: Prohibited and Restricted Ingredients.”

---

Georden Jones is the founder of The Peer Review. Read the full story.